ValuEngine upgraded shares of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) from a strong sell rating to a sell rating in a report released on Thursday morning.

Separately, Wells Fargo & Company raised Infinity Pharmaceuticals from a market perform rating to an outperform rating in a research report on Thursday.

Infinity Pharmaceuticals (NASDAQ:INFI) last issued its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.12). During the same period last year, the firm earned $1.05 earnings per share.

ILLEGAL ACTIVITY WARNING: “Infinity Pharmaceuticals, Inc. (INFI) Upgraded by ValuEngine to “Sell”” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/10/13/infinity-pharmaceuticals-inc-infi-upgraded-by-valuengine-to-sell.html.

In other news, insider Value Fund L. P. Biotechnology bought 1,600,046 shares of the business’s stock in a transaction that occurred on Wednesday, October 4th. The shares were acquired at an average cost of $1.26 per share, with a total value of $2,016,057.96. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 6.81% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in Infinity Pharmaceuticals by 27.7% in the 1st quarter. Vanguard Group Inc. now owns 4,701,769 shares of the biotechnology company’s stock valued at $15,187,000 after purchasing an additional 1,021,128 shares in the last quarter. Wellington Management Group LLP increased its holdings in Infinity Pharmaceuticals by 4.8% in the 1st quarter. Wellington Management Group LLP now owns 4,565,947 shares of the biotechnology company’s stock valued at $14,748,000 after purchasing an additional 207,876 shares in the last quarter. Platinum Investment Management Ltd. increased its holdings in Infinity Pharmaceuticals by 62.6% in the 1st quarter. Platinum Investment Management Ltd. now owns 810,232 shares of the biotechnology company’s stock valued at $2,617,000 after purchasing an additional 312,000 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Infinity Pharmaceuticals by 32.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 652,481 shares of the biotechnology company’s stock valued at $1,024,000 after purchasing an additional 160,814 shares in the last quarter. Finally, Legal & General Group Plc increased its holdings in Infinity Pharmaceuticals by 2,430.0% in the 2nd quarter. Legal & General Group Plc now owns 349,346 shares of the biotechnology company’s stock valued at $548,000 after purchasing an additional 335,538 shares in the last quarter. Hedge funds and other institutional investors own 67.47% of the company’s stock.

Infinity Pharmaceuticals Company Profile

Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.

Receive News & Stock Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.